Boston Scientific announced positive 12-month data from IMPERIAL trial
Boston Scientific announced positive 12-month data from the IMPERIAL trial, the first head-to-head drug-eluting stent trial in the superficial femoral artery. The IMPERIAL trial evaluated the Eluvia Drug-Eluting Vascular Stent System versus the Zilver PTX Drug-Eluting Peripheral Stent in patients with symptomatic peripheral artery disease. PAD occurs when fatty or calcified atherosclerotic material, called plaque, builds up on the walls of the arteries of the legs, restricting blood flow and causing pain, swelling, ulceration and in some cases, the need for amputation of the affected limb. Stents are commonly used to restore and maintain blood flow, reducing symptoms and improving quality of life. In the IMPERIAL trial, the Eluvia stent, which utilizes a drug-polymer combination to offer sustained release of the drug paclitaxel, exhibited superior rates of primary patency, a measure of the target vessel remaining unobstructed at 12 months, and thus able to provide sufficient blood flow to the lower limbs.1 Patients in the Eluvia arm of the study also experienced higher rates of freedom from target lesion revascularization, thus reducing their need for repeat procedures at one year, when compared to those treated with the drug-coated Zilver PTX.